Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,037.56 +19.17 (+0.38%) Dow
38,073.98 +170.69 (+0.45%) Nasdaq
15,720.56 +115.08 (+0.74%) Bitcoin USD
59,405.02 +2,542.29 (+4.47%) CMC Crypto 200
1,278.62 +7.87 (+0.62%)
XNCR May 2024 35.000 call
| Previous close | 0.2500 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 35.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2500 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 40 |
ZacksXencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Business WireXencor Appoints Bart Cornelissen as Chief Financial Officer
PASADENA, Calif., April 09, 2024--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at
GuruFocus.comInsider Sell: SR. VICE PRESIDENT & CFO John Kuch Sells 4,474 Shares of Xencor Inc (XNCR)
John Kuch, Senior Vice President & Chief Financial Officer of Xencor Inc (NASDAQ:XNCR), has sold 4,474 shares of the company on March 5, 2024, according to a recent SEC filing.
